Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been given a consensus recommendation of “Hold” by the seventeen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $39.28.

A number of brokerages recently issued reports on SAGE. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Thursday. Wedbush restated a “neutral” rating and issued a $24.00 price objective on shares of Sage Therapeutics in a research report on Wednesday. Morgan Stanley lifted their target price on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. boosted their target price on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, March 26th. Finally, Oppenheimer dropped their price target on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a research report on Thursday.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $13.04 on Friday. Sage Therapeutics has a 12-month low of $10.92 and a 12-month high of $59.99. The stock’s fifty day simple moving average is $20.06 and its 200-day simple moving average is $20.96.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. The firm had revenue of $77.97 million for the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company’s revenue was up 2621.5% compared to the same quarter last year. During the same quarter last year, the business earned ($2.47) earnings per share. On average, equities analysts anticipate that Sage Therapeutics will post -6.06 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

A number of institutional investors have recently made changes to their positions in the business. MetLife Investment Management LLC acquired a new stake in Sage Therapeutics in the 1st quarter valued at $34,000. CWM LLC grew its holdings in shares of Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares in the last quarter. KBC Group NV bought a new position in shares of Sage Therapeutics in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. raised its holdings in Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 748 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Sage Therapeutics during the first quarter valued at approximately $209,000. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.